These results implied the high MAP1A/1S expression could serve as potential personalized therapeutic targets for patients with NSCLC, and the high MAP2/4/6/7/7D3 expression could serve as biomarkers for favorable prognosis in NSCLC. The gene discussed is MAP2; the disease is non-small cell lung carcinoma.